Team photo


Mogrify is a UK Limited company with an Australian wholly owned subsidiary that aims to transform the development of life-saving cell therapies.

The Company has developed a proprietary direct cellular conversion platform technology that, for the first time, makes it possible to routinely transform (transmogrify) any mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state.

Leveraging data from next-generation sequencing and regulatory networks (DNA-protein & protein-protein), the platform takes a systematic big-data approach to identify the transcription factors (in vitro) or small molecules (in vivo), needed to convert, maintain and culture a target cell phenotype.

Mogrify can perform cell conversions from any starting cell type giving it the best opportunity to address challenges associated with efficacy, safety and scalability that are currently meaning cell therapy is underperforming its undoubted potential.

The platform is protected by the foundational patent application and a suite of additional patent applications covering improvements to the core platform and specific cell conversions, and the Company is commercializing this via a business model of therapeutic development and licensing of novel cell conversion IP to partners engaged in cell therapy development ($35 billion USD by 2023) and cell line development for industrial bioprocessing and research tools ($2 billion by 2031).

Further, through its internal development and partnership programs, the Company is positioned to directly address growing markets that are unserved by current approved cell therapies, such as cardiac repair and cartilage regeneration end-user markets, estimated to be worth $120 billion USD and $7 billion USD by 2022 and 2025, respectively.

In February 2019, Mogrify raised $3.7 million USD seed funding from Ahren Innovation Capital, 24Haymarket and Dr. Darrin M. Disley, OBE in 2019 and is in the late stages of closing a significant Series A fund-raise.

If you have ambition to back a game-changing technology platform and proven management team who aspire to become leading players in the cell therapy market, we would like to hear from you.



Ahren LP is an investment fund that supports transformational companies at the cutting edge of deep science and deep tech. The technologies of its Founding Partners are today valued more than $100 billion combined. A group of highly diverse, creative and original thinkers leading their domains, Ahren believes in taking considered risk that will deliver superior rewards – capturing a generational opportunity to provide smart capital to deep technology pioneers. With a philosophy espousing the importance of relationships and trust, Ahren provides long-term capital and support to exceptional founders and teams, empowering them to achieve the unimaginable. Ahren Innovation Capital was founded by Alice Newcombe-Ellis, together with Science Partners Sir Shankar Balasubramanian, Professor John Daugman, Professor Zoubin Ghahramani, Professor Steve Jackson, Professor Andy Parker, Sir Venki Ramakrishnan, Lord Martin Rees and Sir Gregory Winter.

24Haymarket is a premium deal-by-deal investment platform focused on high-growth businesses, investing up to £5 million in any company. 24Haymarket’s Investor Network includes several highly experienced private equity and venture capital investors, seasoned entrepreneurs and senior operators. We invest our own capital in direct alignment with entrepreneurs and typically seek Board representation to actively support their growth agenda. Since its inception in 2011, 24Haymarket has invested in more than 50 high-growth businesses.


Dr. Darrin M. Disley, OBE

Darrin is a renowned scientist, entrepreneur, angel investor and enterprise champion who has started, grown or invested in over 40 start-up life science, technology and social enterprises, raising $500 million USD in business financing and closing $600 million USD in commercial deals. He was CEO of Horizon Discovery Group plc for 11 years, during which he led the Company from start-up through a $113 million USD IPO, and rapid scale-up powered by multiple acquisitions of US peer companies to become a global market leader in gene editing and gene modulation technologies. He was appointed OBE in 2018 for his services to business and enterprise in the healthcare sector.


25 Cambridge Science Park
Milton Road